• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Celyad - Articles and news items

nkr-2

Celyad and ONO strike deal for NKR-2 in Japan, Korea and Taiwan

Industry news / 11 July 2016 / Victoria White, Digital Content Producer

This license agreement opens new markets to Celyad and expands the global footprint of its NKR-2 T-cell cancer immunotherapy treatment…

c-cure

Results in from Phase III CHART-1 study of C-Cure

Industry news / 28 June 2016 / Victoria White, Digital Content Producer

Celyad has announced headline results for CHART-1, its European Phase III clinical trial for its lead cardiovascular disease product candidate – C-Cure…

nkr-2

First patient treated in fourth dose level NKR-2 Phase I/IIa trial

Industry news / 23 June 2016 / Victoria White, Digital Content Producer

The study is evaluating Celyad’s NKR-2 T-cell therapy using T-cells with NKG2D receptor in patients suffering from AML or multiple myeloma…

nkr-2

Safety follow-up completed for third dose level of NKR-2 trial

Industry news / 26 May 2016 / Victoria White, Digital Content Producer

Celyad has completed the safety follow-up of the third dose level cohort in its Phase I/IIa clinical trial of its NKR-2 T-cell therapy…

nkr-2

Celyad posts an update on its NKR-2 Trial

Industry news / 30 March 2016 / Victoria White

Celyad has announced the completion of the safety follow-up of the first patient in the third dose level in the Phase I/IIa of its NKR-2 T-cell therapy…

nkr-2

Celyad completes safety follow-up in the second dose level of patients in its NKR-2 trial

Industry news / 25 February 2016 / Victoria White

The Phase I trial is designed to assess the safety and feasibility of NKR-2, in two different haematological indications…

NKR T-cells

Directing a weaponised attack on cancer with Natural Killer Receptor T-Cells

Blog / 23 February 2016 / Dr Frédéric Lehmann, VP Immuno-Oncology, Celyad

Natural killer receptor T-cells have the potential to become a real game changing treatment for patients with cancer. Here, Dr Frédéric Lehmann, VP Immuno-Oncology, Celyad, discusses this new cancer fighting technology…

celyad

Celyad appoints new Vice-President of Global Regulatory Affairs

Industry news / 3 February 2016 / Victoria White

Celyad has appointed Dr Richard Mountfield as Vice-President of Global Regulatory Affairs…

NKG2D

Celyad’s NKG2D CAR T-cell therapy completes 30-day safety follow-up

Industry news / 5 January 2016 / Victoria White

CAR-NKG2D is a chimeric antigen receptor (CAR) T-Cell autologous therapy that has the potential to target ligands present on a broad range of solid tumours and blood cancers…

c-cure

FDA authorises Phase III IND for Celyad’s C-Cure and C-Cathez

Industry news / 21 December 2015 / Victoria White

The FDA has authorised Celyad’s IND application to proceed, thus allowing for the clinical testing of C-Cure cardiopioetic cells delivered via C-Cathez in a Phase III heart failure trial…

NKG2D

Second cohort of NKG2D CAR T-Cell Phase I Trial commences

Industry news / 2 December 2015 / Victoria White

Celyad has announced the infusion of the first patient of the second cohort of its Phase I clinical trial evaluating it’s NKG2D CAR T-Cell therapy in acute myeloid leukaemia and multiple myeloma…

Roychowdhury

Celyad appoints Dr Debasish Roychowdhury as non-executive director

Industry news / 7 September 2015 / Victoria White

Dr Roychowdury brings over 15 years of comprehensive pharmaceutical industry experience and 14 years of patient care and academic research to the role with Celyad…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +